Phagelux Inc., of Shanghai, said it entered definitive purchase agreements of preferred stock with a group of institutional investors, including both existing and new investors, to raise $10 million, with the company issuing an aggregate of 176,796 shares of series A preference stock. The company, which has both human health and agrihealth divisions, is developing antibacterial solutions across multiple fields utilizing various phage and phage-based technologies and solutions.